NEW YORK (GenomeWeb News) – Almac's diagnostics business today said that it has received a clinical laboratory permit from New York, allowing it to receive clinical samples from the state for clinical testing and trial management.
Additionally, the UK-based firm said that it retained its CAP and CLIA accreditation following an inspection by the College of American Pathologists. Almac received CLIA certification in early 2011.
Almac's diagnostics unit focuses on prognostic and predictive tests and partners with biopharmaceutical firms to develop companion diagnostic tests. It also develops and offers? diagnostic tests for diseases including breast, colon, ovarian, prostate, and lung cancer.